The TNF-Related Apoptosis Inducing Ligand (TRAIL) cytokine triggers apoptosis specifically in cancer cells. Susceptibility of a given cell to TRAIL depends on the activity of regulatory proteins, one of the most important of which is BID. The aim of this study was to increase the cytotoxic potential of TRAIL against cancer cells. TRAIL was fused to the BH3 domain of BID. Hence, TRAIL acted not only as an anticancer agent, but also as a specific carrier for the BID fragment. Two fusion protein variants were obtained by genetic engineering, harboring two different linker sequences. The short linker allowed both parts of the fusion protein to fold into their native structures. The long linker influenced the structure of the fused proteins but nonetheless resulted in their highest cytotoxic activity. Optimal buffer formulation was determined for all the analyzed TRAIL variants. Fusing the BH3 domain of BID to TRAIL improved the cytotoxic potential of TRAIL. Further, these findings may be useful for the optimization of other anticancer drugs based on TRAIL, since the appropriate formulation would secure their native structures during prolonged storage.
Introduction
TNF-Related Apoptosis Inducing Ligand (TRAIL) plays an important role in the regulation of antiviral, anticancer and autoimmune responses by triggering apoptosis in malfunctioning cells. Similar to other members of the TNF superfamily, TRAIL is bioactive as a trimer. However, unlike other death agonists, TRAIL coordinates a zinc ion that confers the protein's activity and specificity (Walczak et al., 1999) . TRAIL is a transmembrane protein but it may be cleaved by matrix metalloproteinases; the liberated extracellular fragment is also bioactive (Mariani and Krammer, 1998) . The binding of TRAIL to its receptors DR-4 or DR-5 results in an intracellular formation of death-inducing complex (DISC), which activates caspase-8, leading to the activation of effector caspases (Kischkel et al., 2000) . If administered intravenously, TRAIL accumulates in the cancer tissue, leaving the healthy tissues unaffected (Herbst et al., 2010) . However, many cancer cell lines accumulate mutations that render them resistant to apoptosis induced by TRAIL. Signal transduction pathways within these cells are modified by altered expression of particular regulatory proteins. In many cell lines, the extracellular apoptotic stimuli are insufficient to initiate the programmed death. Such cells, often described as type II cells, require also the mitochondrial apoptotic pathway to initiate efficient transduction of an apoptotic signal (Özören and El-Deiry, 2002) . Susceptibility of those cells to TRAIL depends on the activity of proteins from the BH3 family, especially BID (Spencer et al., 2009) . Özören and El-Deiry (2002) demonstrated that in the SW480 colon cancer cells, the proteolytic processing of BID into tBID, its truncated form, is the limiting step of the initiation of mitochondrial apoptosis and thus, it forms the basis for cancer cell classification regarding the programmed death pathways. Furthermore, in cells resistant to the extracellularly induced apoptosis, stabilization or accumulation of tBID, in combination with death receptor agonists (i.e. TRAIL ligand or antibody), exert a strong synergistic effect that abolishes the resistance (Cristofanon and Fulda, 2012; Sung et al., 2012) . On the other hand, silencing of BID protects from TRAILinduced apoptosis (Garnett et al., 2007) . This clearly indicates the important role of tBID as the universal regulator that can promote mitochondrial apoptosis in both types of cancer cells.
Considering the above, we constructed two new TRAIL variants, aiming to increase the antitumor effect of TRAIL in the established cancer cell lines by fusing it with the BH3 domain of BID, i.e. the expected key intracellular enhancer of the pro-apoptotic signal. TRAIL acted not only as an anticancer agent, but also as a specific carrier of the BID fragment. Such approach was previously shown to increase the selectivity of a prospective anticancer treatment (Guillen et al., 2017) . The cytotoxicity of the designed fusion proteins was higher than that of TRAIL alone.
Materials and Methods

Cloning
Genes encoding proteins AD-O57.4 and AD-O57.5, originating from human TRAIL and BID, were synthesized by GENEART AG (currently Thermo Fisher Scientific) and cloned into the standard cloning vector pMA (GENEART). The resultant constructs pMA. AD-O57.4 and pMA.AD-O57.5 were digested with NdeI and XhoI. Restriction fragments containing the ad-o57.4 or ad-o57.5 genes were ligated with the pET30a expression vector (Novagen, MerckChemicals Ltd) also digested with NdeI and XhoI. Escherichia coli DH5α competent cells (Agilent) were then transformed with the ligation mixtures. Plasmid DNA isolated from the transformants was sequenced and the sequences of the obtained plasmids pET30a.AD-O57.4 and pET30a. AD-O57.5 were verified. To produce untagged proteins, the plasmids were used to transform E. coli BL21-CodonPlus(DE3)-RIL strain (Agilent).
Protein expression
Seed cultures were prepared in 500-mL Erlenmeyer flasks containing 200 mL of TB medium (Novagen) and 50 μg/mL kanamycin (Sigma), by loop inoculation with a colony from a LB agar plate. The cultures were incubated overnight at 37°C, at 250 rpm, on a rotary shaker (Innova, New Brunswick Scientific). Batch fermentations were carried out in a 6.6-L BioFlo 310 bioreactor (New Brunswick Scientific), containing 4 L of TB medium (Novagen) supplemented with 0.25% (w/v) glucose and 50 μg/mL kanamycin. The conditions of operation were as follows: temperature of 37°C (30°C after induction of protein production); 40% dissolved oxygen; and pH 6.9. The pH was controlled by the addition of NH 4 OH. The growth was initiated by the inoculation of TB medium with the seed culture (1:50). The expression of AD-O57.4 and AD-O57.5 proteins was induced with 0.5 mM IPTG (Novagen) at OD 600 = 0.6-0.8. After 4 h, the cultures were harvested by centrifugation at 9000 × g for 10 min at 4°C. Bacterial pellets were stored at −20°C.
Purification of AD-O57.4
The pelleted E. coli BL21-CodonPlus(DE3)-RIL/pET30a.AD-O57.4 cells were suspended in lysis buffer containing 50 mM Tris-HCl (pH 7.5), 5 mM DTT, 10% (v/v) glycerol, and 1 mM PMSF (1:6, m/v, cell:buffer ratio). The cells were disrupted with Emulsi-Flex C3 (Avestin). The obtained lysate was centrifuged at 18.000 × g for 60 min at 8°C. The supernatant was applied onto a column packed with Fractogel EMD SO 3 − (S) (Merck Millipore). Unbound proteins were washed out with one column volume (CV) lysis buffer. Proteins were eluted with 5 CV 0-40% and 1 CV 40-50% of buffer containing 50 mM Tris-HCl (pH 7.5), 5 mM DTT, 10% (v/v) glycerol and 2 M NaCl. The wash and separation steps were performed at 8-14°C, with a flow of 5 mL/min. The presence of AD-O57.4 in fractions collected during the separation was checked by SDS-PAGE. Samples containing this protein were pooled and formulated using Sephadex G-25 pre-packed HiPrep 26/10 desalting columns into the final buffer containing 50 mM Tris-HCl (pH 8.0), 200 mM NaCl, 5 mM glutathione, 0.1 mM ZnCl 2 , 80 mM sucrose and 10% (v/v) glycerol.
Purification of AD-O57.5
Bacterial cell lysis was performed as described for AD-O57.4. After centrifugation, the supernatant was discarded and the pellet was washed four times, similarly as in the lysis step above. The washed inclusion bodies were suspended in a buffer containing 50 mM TrisHCl (pH 8.5), 5 mM 2-mercaptoethanol, 50 μM ZnCl 2 and 800 mM L-arginine, and kept for 24 h with stirring at 4°C. The suspension was then centrifuged at 18.000 × g for 40 min at 4°C. NaCl was added to the supernatant containing the solubilized AD-O57.5 to a final concentration of 2 M. The protein solution was dialyzed against a buffer containing 50 mM Tris-HCl (pH 8.5), 5 mM 2-mercaptoethanol, 50 μM ZnCl 2 , 100 mM NaCl, 80 mM sucrose and 250 mM L-arginine. The solution was concentrated using Amicon Ultra15 device (Merck Millipore) with a 10-kDa cutoff membrane, and was formulated on Sephadex G-25 pre-packed HiPrep 26/10 desalting columns into the final buffer of 50 mM Tris-HCl (pH 8.0), 200 mM NaCl, 5 mM glutathione, 0.1 mM ZnCl 2 , 80 mM sucrose and 10% (v/v) glycerol. The expression and purification of TRAIL (aa 114-281) were conducted as described previously (Pieczykolan et al., 2014) .
Structure analysis
Prior to circular dichroism (CD) and fluorescence spectra acquisition, the proteins were reformulated either into the minimal buffer formulation [25 mM Tris-H 2 SO 4 (pH 8.0), 50 mM Na 2 SO 4 , 10 μM ZnCl 2 and 2 mM DTT] or the optimal formulation [50 mM TrisHCl (pH 8.0), 200 mM NaCl, 10% (v/v) glycerol, 80 mM sucrose, 10 μM ZnCl 2 and 2 mM DTT] using the HiTrap desalting columns (GE Healthcare Life Sciences). For measurements at pH 4.0, the buffering agent was changed to 50 mM sodium acetate. The reformulation buffer solutions were used as blanks and their spectra were subtracted from the raw data. Protein concentration during the experiments was 0.14-1.6 mg/mL, determined by the Bradford assay (Bradford, 1976) .
Fluorescence measurements were performed at 20°C using the Fluorolog FL3-12 fluorimeter (Jobin Yvon) equipped with a CF31 temperature control unit (Julabo) in 3 × 3 mm path-length cuvettes (Hellma). Protein concentration was adjusted to 5 μM. Spectra were collected in the 301-450-nm range, with excitation at 295 nm, 1-nm increments, 0.2-s integration time and 3.2 × 3.2 nm slits. The spectra were averaged over three acquisitions and smoothed using the 7 pt Savitzky-Golay algorithm.
CD measurements were conducted at 25°C using the J-710 spectropolarimeter (Jasco) equipped with an F25 temperature control unit (Julabo), in 0.1-mm path-length 106-QS cuvettes (Hellma). Spectra were collected in the 200-250 nm (far-UV) or 250-350 nm (near-UV) ranges, with 100 mdeg sensitivity, 1-nm data pitch, 20 nm/min scanning speed, 4-s response time and 2-nm bandwidth. The spectra were averaged over five acquisitions and smoothed using the 7 pt Savitzky-Golay algorithm. Secondary structure content was evaluated using the CDPro program package (Sreerama and Woody, 2000) .
Size-exclusion chromatography (SEC) experiments were performed using the ÄKTApurifier liquid chromatography system (Amersham Biosciences), on a Superdex 200 column (GE Healthcare Life Sciences). Chromatography was carried out at a flow rate of 0.5 mL/min and monitored by measuring the absorbance at 280 nm. The column was calibrated using the following standard proteins: thyroglobulin (669 kDa), apoferritin (440 kDa), bovine serum albumin (67 kDa), CAP (47.2 kDa) and myoglobin (17.6 kDa). The column void volume (V 0 ) was 7.8 mL, and the column total volume (V c ) was 20.9 mL.
Purified TRAIL variants (0.1-0.4 mg/mL in 0.2 mL) were loaded on the column. The elution volume of each protein was used to calculate the partition coefficients K AV . The molecular masses of the standard proteins were plotted against the corresponding K AV factors, and standard curves were fitted to calculate the apparent masses of the TRAIL variants.
Proteolytic digestion
Proteolytic cleavage with matrix metalloproteinase-9 (MMP-9) (R&D Systems) was performed according to the manufacturer's protocol. The reaction mix contained 20 or 200 nM MMP-9 and 5-50 μM substrate in TCNB buffer [50 mM Tris-HCl (pH 7.5), 10 mM CaCl 2 , 150 mM NaCl, 0.05% (w/v) Brij-35 and 5 mM DTT]. Samples were incubated at 37°C. Aliquots taken at the specified time points were denatured thermally and chemically, and subjected to SDS-PAGE. The gels were stained with Coomassie Brilliant Blue R-250 (Fluka). The amount of protein in each band was quantified using the GelAnalyzer 2010 (Lazar Software).
Stability analysis
Differential scanning fluorimetry (DSF) measurements were performed using the 7500 Fast Real-Time PCR System (Applied Biosystems), in MicroAmp 96-well plates (Applied Biosystems). Each sample contained 0.1 mg/mL protein and 5× concentrated SYPRO Orange dye (Sigma-Aldrich). The reference formulation buffer contained 50 mM CH 3 COONa, 50 mM Tris-HCl, 50 mM BisTris, 50 mM H 3 BO 3 , 100 mM NaCl, 10% (v/v) glycerol, 80 mM sucrose, 0.1 mM ZnCl 2 and 5 mM DTT. The fluorescence signal intensity was recorded at the Cy3 excitation/emission settings, in the range of 20-95°C, at ca. 1°C/min scan rate. Normalized fluorescence intensity values were plotted against temperature and melting temperature (T m ) values were determined as the transition midpoints. Each experiment was performed in quadruplicate.
Chemical stability of the proteins was assessed by measuring sample fluorescence at 316 nm, i.e. the wavelength at which the biggest difference in fluorescence between the native and denaturing conditions was observed. Samples containing 5 μM protein and 0-4 M guanidine hydrochloride were incubated at 20°C for 1 h prior to the measurements. Fluorescence was measured at 20°C using the Fluorolog FL3-12 fluorimeter (Jobin Yvon) equipped with the CF31 temperature control unit (Julabo) in 3 mm path-length cuvettes (Hellma), with 0.2 s integration time, 3-4 nm slits, and averaged over three acquisitions. The signal was normalized to 0-1 range to calculate the fraction of folded protein and the apparent free energy change using Boltzmann curve fit, as described elsewhere (Batra et al., 2016) . The experiments were performed in triplicate.
Cytotoxicity assay
All cell lines were purchased from ATCC. A549, NCI-H460 and NCI-H2122 cells were maintained in the RPMI-1640 medium (Gibco); HepG2, SK-MES-1 and CCD11Lu cells were maintained in the minimum essential medium (Gibco); and HCT116 and MES-SA/ Dx5 cells were maintained in the McCoy's medium (Gibco). All culture media were supplemented with 10% (v/v) fetal bovine serum (Gibco), 0.1 mg/mL streptomycin and 100 U/mL penicillin (Biowest). The cells were grown under standard conditions (i.e. 37°C, 5% CO 2 and 95% humidity) and passaged with 0.25% (w/v) trypsin-EDTA at ca. 80% confluence. During the course of the experiment, microbiological purity of the cell lines was checked using the Mycoplasma detection kit (InvivoGen).
Cells were seeded in 96-well cell culture plates. The following day, the cells were treated with different concentrations of the tested proteins, with the incubations continued for the next 72 h. The proteins were formulated in 50 mM Tris-HCl (pH 8.0), 200 mM NaCl, 5 mM glutathione, 0.1 mM ZnCl 2 , 80 mM sucrose and 10% (v/v) glycerol. The cells were then incubated with 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT; 100 μg per well) at 37°C for 3 h. Finally, the medium containing MTT was removed and the formazan crystals were dissolved by the addition of 100 μl of DMSO. After mixing, the absorbance at 570 nm was measured (690 nm reference filter) using a Microplate Reader EON (BioTek). The experiments were performed in triplicate.
Results
Construct design
Constructs AD-O57.4 and AD-O57.5 were designed in Adamed Group as part of the ONCO-3CLA program. In both proteins, the BH3 domain of BID protein was fused N-terminally to the soluble fragment of a TRAIL monomer (Fig. 1) . A similar conception of proteins containing TRAIL-fused peptides was employed previously, with TRAIL and Smac/Diablo fragments (Pieczykolan et al., 2014) . Regardless of the TRAIL fragment used for crystallization, all the known crystal structures contain electron density for residues starting with P119 or Q120 (Cha et al., 1999; Hymowitz et al., 1999 Hymowitz et al., , 2000 Mongkolsapaya et al., 1999) . Because of this, the fusion proteins were designed to contain the core 120/121-281 aa fragment of TRAIL. The fragment was located at the C-terminus of the constructs to enable trimerization.
The two parts of the fusion proteins were separated by sequences recognized by the matrix metalloproteinases MMP-9 and uPA, which are frequently overexpressed in metastasizing cells. Since the BID fragment was expected to act intracellularly, the construct was BID, BH3 domain of the BID protein (aa 84-99); R 8 , eight consecutive arginine residues; uPA, urokinase cleavage site; MMP-9, matrix metalloproteinase-9 cleavage site; C 3 , glycine-serine spacer containing three cysteine residues (GGGCAAACAACGSG); TRAIL, soluble fragment of the TRAIL monomer (AD-O57.4: aa 121-281; AD-O57.5: aa 120-281).
additionally equipped with an octa-arginine sequence, enabling the penetration through the cell membrane (Futaki et al., 2001) . The two variants harbored linkers of different lengths (Fig. 1) . The linker in AD-O57.4 only contained the MMP-9 and uPA sites, and the octa-arginine sequence; the linker in AD-O57.5 also included a glycine-serine spacer and three additional cysteine residues, intended to form disulfide bridges that would link the juxtaposed subunits and thus stabilize the trimer. A TRAIL fragment (aa 114-281), further referred to as 'TRAIL', was also generated, and used as a reference in the structure and bioactivity analyses.
Optimal formulation
The initial screening to identify the formulation for optimal protein stability involved a high-throughput method, i.e. DSF. In DSF, the use of a reporter dye enables rapid determination of the protein T m under various conditions and in a microplate format. First, we analyzed the effect of pH on protein stability ( Fig. 2A) . To ensure similar composition of the samples, four buffering agents were used simultaneously in each sample, selected to cover the entire pH range. The optimal pH for all proteins was found to fall between 7.0 and 8.0 pH units. Acidification reduced the protein stability to a greater extent than alkalization. Over the entire analyzed pH range, the highest T m values were obtained for TRAIL and the lowest for AD-O57.4. Considering the dependence of T m on pH, further screening was conducted at three different pH values: 5.0, 7.0 and 9.0.
The T m increased with increasing ionic strength, for both sodium chloride and ammonium sulfate. Figure 2B shows the dependence of T m on NaCl concentration at pH 5.0, where the trend was most pronounced. A similar pattern was also observed at pH 7.0 and 9.0. Further, 1 M ammonium sulfate stabilized the proteins more effectively than 1 M sodium chloride. Apart from NaCl and ammonium sulfate, glycerol, sucrose and chelating agent EDTA were also tested for their influence on the proteins' stability ( Fig. 2C and E) . The greatest increase in T m was caused by 10% glycerol and 1 M ammonium sulfate. In some cases, sucrose also stabilized the proteins, especially at pH 5.0, but the effect of the osmolytes was not additive. The effect of EDTA was minor, with the changes of T m not exceeding 4°C. Similarly to the initial experiments when various pH values were tested, the highest T m values were obtained in each case for TRAIL, and the lowest values for AD-O57.4. Regardless of the formulation, all the proteins exhibited the lowest stability at pH 5.0 and highest stability at pH 7.0.
Structural characterization
We then analyzed parameters of the secondary, tertiary and quaternary structure of AD-O57.4 and AD-O57.5, and compared them with those of TRAIL. Firstly, CD spectra in the far-UV range (Fig. 3A) were evaluated to assess the secondary structure content of the three proteins. The shape of the TRAIL spectrum was characteristic for β proteins; it exhibited a minimum at 222 nm, and maxima at 233 nm and ca. 195-200 nm. Similar spectra were reported previously for TRAIL (Hymowitz et al., 2000; Nam and Choi, 2002; Fan et al., 2015) . Spectra of the fusion proteins AD-O57.4 and AD-O57.5 lacked the 230-nm maximum and the other two bands were blue-shifted. The changes were more profound for AD-O57.5 than AD-O57.4.
To obtain quantitative information on the secondary structure content, the CD spectra were analyzed using the CDPro software package (Sreerama and Woody, 2000) . The number of residues forming helices and sheets agreed very well with the values calculated based on the TRAIL crystal structure (Hymowitz et al., 2000, PDB: 1DG6) and the BID NMR structure (Chou et al., 1999 , PDB: 2BID) (see Supplementary Table SI) : all three proteins mostly contained β structure, which also dominated in the TRAIL structure; the helix content was increased in the two fusion proteins, which was consistent with the presence of the all-α-helical BH3 domain. This allowed us to conclude that both fused fragments folded forming their native structures. AD-O57.5 comprised eight more helix-forming residues than AD-O57.4, with a similar content of β structure and turns. This could result from the helix propagating from the BH3 domain to the N-terminal part of the linker.
CD spectra of TRAIL and AD-O57.4 in the near-UV range (Fig. 3B) were typical for tryptophan residues, with two negative bands at ca. 280 nm. This implies chromophore immobilization in an asymmetric milieu within the protein structure. Similar spectrum for the soluble TRAIL fragment was described previously (Nam and Choi, 2002) . On the other hand, the spectrum of AD-O57.5 had a different shape, with a strong positive band at 267 nm. Such CD signal can arise from disulfide bonds (Kahn, 1979) . The fluorescence spectra of the three proteins were similar (Fig. 3C) , which implied that their tryptophan residues were located inside the protein molecules and partially shielded from to the solvent.
The BH3 domain of BID lacks tryptophan residues, while TRAIL contains two: Trp154, buried in the protein core distal to the receptor, and Trp231, adjacent to the zinc coordination site (Fig. 3D) , at the trimer interface. The fluorescence and CD signal of the latter is sensitive to the presence of the zinc ion, as the disordered EF loop (aa 229-236) becomes rigid upon chelation of the ion (Hymowitz et al., 2000) . Thus, detection of a signal from a tryptophan immobilized in an asymmetric environment inside the protein molecule indicated that the generated proteins indeed coordinated zinc ions.
SEC was then employed to determine the oligomerization status of the three proteins. A single peak was observed for each protein. The corresponding elution volume was then used to calculate the apparent molecular mass, i.e. 60 kDa for TRAIL; 64 kDa for AD-O57.4; and 52 kDa for AD-O57.5. The molecular masses of TRAIL and AD-O57.4 corresponded to a trimer, while that of AD-O57.5 corresponded to a dimer. The SEC traces are shown in Supplementary Fig. S1 . AD-O57.5 dimerization could be caused by disulfide bond formation, since its linker included three cysteine residues in addition to the sole Cys230 residue in the TRAIL monomer. To verify this hypothesis, SDS-PAGE was performed in the presence of various concentrations of the reducing agent DTT (Fig. 3E) . Regardless of DTT concentration, TRAIL and AD-O57.4 migrated predominantly as monomers, while the oligomeric form of AD-O57.5 depended on the redox potential: in the absence of DTT, the protein formed dimers and higher-order species, possibly aggregates; in the presence of 5 mM DTT, the protein formed monomers and dimers; the presence of 50 mM DTT resulted in complete monomerization of AD-O57.5. These observations confirmed the notion that AD-O57.5 had a tendency to form intermolecular disulfides, probably between the cysteine residues introduced in the linker.
Comparison of the activity and proteolytic susceptibility of AD-O57.4 and AD-O57.5
The fusion proteins were designed to undergo proteolysis in the vicinity of the tumor, releasing two peptides, i.e. fragments of the TRAIL and BID proteins. The in vitro cleavage with proteinase MMP-9 was much slower in the case of AD-O57.4 than AD-O57.5 (Fig. 4A-C) . For instance, a 2-h incubation at a 1:250 proteasesubstrate ratio led to the proteolysis of 93% of AD-O57.5 but of only 14% of AD-O57.4. Such a pronounced difference in the cleavage efficiency was probably associated with the smaller steric hindrance for the long linker in AD-O57.5.
Interestingly, the proteolytic susceptibility of the fusion proteins correlated with their cytotoxic activity, as determined in the MTT assay in several cell lines (Fig. 4D ). For each cell line, the determined For each sample, the melting temperature was determined as the midpoint of the SYPRO Orange fluorescence intensity increase. The presented values are averages from four independent measurements. Error bars indicate standard deviations. *P < 0.05; **P < 0.01; ***P < 0.001 (unpaired t-test).
IC 50 was highest for TRAIL, lower for AD-O57.4, and lowest for AD-O57.5. Both fusion proteins induced apoptosis in three lines that were originally resistant to TRAIL, namely, A549, MES-SA/ Dx5 and HepG2. No TRAIL variant exhibited any cytotoxicity toward the non-transformed line CCD11Lu. These observations suggested that the introduced modifications selectively enhanced TRAIL cytotoxicity against cancer cells.
Stability evaluation
After analyzing the protein structure and activity, we investigated in greater detail the structural changes underlying the protein stability drop at pH 4.0. CD and fluorescence spectroscopy, and SEC were employed, and evidenced a global structural change in the three proteins. Namely, the protein hydrodynamic radii increased, the emission maxima red-shifted, and the intensity of the near-UV CD signal decreased. Further, the secondary structure content changed in favor of a helical structure (see Supplementary Fig. S2 ). These observations suggested increased conformational freedom and heterogeneity, indicating a molten globule-like state. They were consistent with the observations of Nam and Choi (2002) , and thus provide another indication that the TRAIL structure remained unaltered within the generated fusion proteins.
The structural parameters of the TRAIL variants were also altered by EDTA, a potent bivalent cation chelator. Consequently, protein monomerization, decrease and red-shift of the fluorescence intensity, and decrease of the near-UV CD signal were observed ( Supplementary Fig. S2 ). The changes caused by EDTA suggested increased disorder and flexibility of the EF loop. Similar changes in the fluorescence spectra were described for TRAIL mutants lacking the zinc-binding residues (Lee et al., 2007) . This allowed us to conclude that the generated TRAIL variants coordinated zinc ions prior to the EDTA treatment, which was also supported by their high cytotoxicity.
Furthermore, glycerol and sucrose decreased the scope of changes observed in the fluorescence and CD spectra, and SEC traces at pH 4.0 ( Supplementary Fig. S2A-C) and in the presence of EDTA ( Supplementary Fig. S2D-F) . The osmolytes reduced the alteration of structural parameters under these conditions, suggesting that the native protein structure was stabilized. These observations agreed with the outcomes of the aforementioned DSF experiments. In particular they explained the minor T m change observed in DSF upon EDTA addition (Fig. 2C-E) , as the measurements were performed in the rich formulation, containing 10% glycerol and 80 mM sucrose.
For a quantitative description of the stabilizing effect of zinc ions and osmolytes on protein structure, the proteins were chemically denatured by increasing guanidine hydrochloride concentrations and analyzed by fluorescence. The experiments were performed in three different buffer formulations: minimal formulation; optimal formulation, containing osmolytes; and minimal zinc-depleted formulation containing EDTA (Fig. 5) . The data were fit to a two-state model to calculate the apparent free energy change of denaturation, ΔG app . AD-O57.4 was more stable than AD-O57.5. Protein stability was increased by osmolytes and decreased by EDTA (as shown in Fig. 5 ). Results are expressed as the mean ± SD (measurement error could not be calculated in cases where over 50% of cells survived, even at the highest TRAIL concentration tested). *P < 0.05; **P < 0.01; ***P < 0.001 (unpaired t-test).
Some discrepancies were observed between protein stabilities determined based on the melting temperatures and changes in the denaturation free energy (Figs 2 and 5) , since AD-O57.4 exhibited the highest ΔG app but the lowest T m in most formulations. On the other hand, the thermal and chemical denaturation data agree much better with respect to the effect of specific excipients on the stability of TRAIL variants. The presence of EDTA resulted in the reduction of both ΔG app and T m . The addition of osmolytes and increased salt concentration increased both ΔG app and T m in the three proteins (Figs 2 and 5) . The thermal and chemical stabilities of a protein are not equivalent and may differently depend on conditions. The differences may stem from the irreversibility of thermal denaturation, non-cooperativity of the transition, different contributions of the enthalpic and entropic components, and heat capacity changes during the transition (Niesen et al., 2007; King et al., 2011) . Nevertheless, thermal stability may be a useful indicator of a protein's half-life (van der Sloot et al., 2004) . Our observations confirmed that such high-throughput scanning methods as DSF, are useful in the initial stages of identifying the optimal buffer formulation, although they should be interpreted with caution and possibly crosschecked by analyzing the actual free energy change.
Discussion
BID protein is considered to be the key regulator that influences the cellular response to the TRAIL pro-apoptotic signal by enhancing the mitochondrial apoptotic pathway. In the current study, by fusing together TRAIL and BID fragments, we were able to increase the ability of TRAIL to induce apoptosis in type II cancer cell lines.
The transmembrane TRAIL protein can undergo proteolysis in vivo (Mariani and Krammer, 1998) . The released extracellular fragment binds to DR4 and exerts cytotoxic effect (Mühlenbeck et al., 2000; Wajant et al., 2001) . Thus, the soluble TRAIL fragment was incorporated in the fusion proteins in the current study. Until now, most studies have employed the soluble, truncated TRAIL fragment (aa 114-281). Regardless of the TRAIL fragment crystallized, all the reported crystal structures contain electron density for residues starting at P119 or Q120 (Cha et al., 1999; Hymowitz et al., 1999 Hymowitz et al., , 2000 Mongkolsapaya et al., 1999) . In the current study, we showed that the secondary structure content of the 114-281 aa fragment was consistent with the crystal structure of the 120-281 aa fragment (Supplementary Table I ). Hence, the additional peptide sequence at the N-terminus of the 114-281 aa fragment probably did not alter its structure compared with the 120-281 aa TRAIL fragment.
Two different linker sequences were tested to optimize the construct. In AD-O57.4, TRAIL and BID fragments were separated only by proteinase cleavage sites and an octa-arginine sequence. In AD-O57.5, the linker was extended to include a glycine-serine spacer and three additional cysteine residues (Fig. 1) , intended to form disulfide bridges between the trimer subunits. The presence of the disulfide bridges was confirmed by CD measurements in the near-UV range (Fig. 3B ), yet it seemed to stabilize the dimeric rather than the trimeric form of AD-O57.5. Perhaps a long linker with a smaller number of cysteine residues would be optimal for the fusion of the BID and TRAIL fragments.
The tested modifications of TRAIL succeeded in increasing its cytotoxicity (Fig. 4D) . Neither protein was toxic to the nontransformed cell line CCD11Lu. On the other hand, the proteins' cytotoxicity was very high in cancer cells, with the IC 50 values mainly in the sub-nanomolar range. The tested cell lines were derived from various tumors and included the multi drug-resistant uterine sarcoma-derived cell line MES-SaDx5. The results were consistent with the previously published observations that BID determines the susceptibility of various cell lines to TRAIL (Garnett et al., 2007; Spencer et al., 2009; Goncharenko-Khaider et al., 2010; Cristofanon and Fulda, 2012; Song et al., 2013; Orzechowska et al., 2014) . Among others, the non-small cell lung cancer cell line A549 was sensitized to TRAIL after intracellular delivery of BID (Orzechowska et al., 2014) . This cell line was also used in the current study. We observed that it was resistant to TRAIL yet sensitive to the generated variants AD-O57.4 and AD-O57.5 (Fig. 4D) .
The long linker in AD-O57.5 allowed for a higher bioactivity than the short linker in AD-O57.4. Similar observations were reported by Fan et al. (2015) , who observed that the bioactivity of Vas-TRAIL fusion proteins containing longer linkers was higher than for TRAIL alone. These longer linkers enabled proper folding of the two fused peptides. In the case of AD-O57.5, 16 additional amino acids constituted a spacer between the sequence recognized by MMP-9 and the TRAIL fragment. This apparently facilitated the interaction between the fused protein and matrix proteinases, and possibly also with TRAIL receptors and other molecular partners, thus allowing for efficient induction of apoptosis in the targeted cells. Differences in the structure and bioactivity observed between AD-O57.4 and AD-O57.5 illustrate the importance of proper linker selection in fusion protein design.
Since the proposed modifications enhanced the cytotoxic potential of TRAIL, we also analyzed their effect on the structure of the fusion proteins. For AD-O57.4, the variant harboring the short linker, all the structural parameters analyzed were similar to TRAIL (Fig. 3) . This indicated that the AD-O57.4 had the expected trimeric structure that corresponded with the known structures of TRAIL and BID. In AD-O57.5, the fusion protein with the long linker, the subunit structure was most likely conserved, with the expected content of particular secondary structure types. However, the design of that protein affected its quaternary structure.
Introduction of additional cysteine residues to the linker resulted in the formation of disulfide bridges, as indicated by the SDS-PAGE analysis and the near-UV range CD measurements ( Fig. 3B and E) . Using SEC, we observed dimer formation, instead of the expected trimer. The formation of disulfide-linked dimers can be augmented by purification from inclusion bodies under denaturing conditions, which was required for the purification of AD-O57.5 but not AD-O57.4. However, other analyses suggested the coexistence of trimeric and dimeric forms of AD-O57.5. Firstly, the CD and fluorescence signals of AD-O57.5 were sensitive to EDTA; on the other hand, the dimeric TRAIL would be incapable of binding zinc ions, since the proper geometry of the chelating Cys230 residues is supported by the 3-fold-symmetric orientation of the subunits. Further, the high cytotoxicity of AD-O57.5 suggests that it retained the trimerization potential, as TRAIL is active solely as a trimer (Hymowitz et al., 2000; Lee et al., 2007) . Perhaps a covalent S-S link between two subunits would not preclude a non-covalent association of a third subunit. Such trimer would be less stable, and thus remain undetected under the non-equilibrium conditions of SEC, in agreement with the observation that AD-O57.5 had the lowest ΔG app among the TRAIL variants tested (Fig. 5) .
Development of bioactive agents requires not only retention of their native structure but also proper buffer formulation, i.e. one where the structure would be most stable, allowing for prolonged storage. We analyzed a number of excipients and found that the three TRAIL variants were most stable in buffers at neutral pH and with high ionic strength ( Fig. 2A and B) . The stabilizing effect of salts suggests the occurrence of destabilizing ionic interactions within the protein molecules, possibly repulsion of Arg227 residues residing at the trimer interface (van der Sloot et al., 2004; Lee et al., 2007) or arginine residues located in the AD-O57.4 and AD-O57.5 linkers. All proteins were also stabilized by osmolytes: glycerol and sucrose, which raised their melting temperatures (DSF analysis; Fig. 2C-E) , and reduced the scope of structural changes at pH 4.0 and in the presence of EDTA (Supplementary Fig. 2 ). The addition of 10% glycerol appeared to be especially critical for protein stability, whereas 80 mM sucrose could be omitted without adversely affecting protein stability.
Osmolytes can modify the protein microenvironment and solvation shell, and may thus influence the ionization state of particular side chains. The resulting difference in charge would affect the distribution of electrostatic forces within the protein molecule and modify its global structure. In the case of zinc chelation by EDTA, osmolytes stabilized the trimeric protein structure even in the absence of the Cys-Zn 2+ coordination bond. In the absence of osmolytes, the remaining forces supporting the trimeric state became insufficient after the zinc ion was removed. Hence, the addition of EDTA to the minimal protein formulation resulted in greater changes in fluorescence and the CD signal than in the optimal formulation ( Supplementary Fig. S2 ).
Our observations interrelate with the broader context of research of the TRAIL structure. Hymowitz et al. (2000) showed that in the absence of zinc ions, the EF loop becomes loose and TRAIL activity diminishes, even though the cation is not directly engaged in the association between TRAIL and the receptor. The relaxation of the EF loop was indicated by the changes in fluorescence and the CD signal (Hymowitz et al., 2000) . Next, Lee et al. (2007) employed site-directed mutagenesis to demonstrate that the rigidity of the EF loop determines the TRAIL activity, even in the absence of zinc ions. We succeeded in stabilizing this crucial region of TRAIL without mutagenesis but just through optimal buffer formulation. Our findings might be especially useful for the optimization of anticancer drugs based on TRAIL. They reveal that an appropriate buffer formulation allows the protein to maintain its native structure during storage, even upon the loss of the zinc ion. Importantly, the proposed stabilizing reagents are suitable for intravenous administration.
To conclude, we proposed two novel, potentially therapeutic proteins that incorporated TRAIL and BID protein fragments, by applying the concept of a concerted targeting of TRAIL and its downstream regulators. The design of the fusion proteins increased their cytotoxicity in cancer cells compared with the TRAIL protein alone. Two linker sequences were tested. The short linker allowed both parts of the fusion protein to fold into their native structures. The long linker affected the quaternary structure of the fused proteins but, nonetheless, the protein that harbored the linker showed the highest activity against all the tested cell lines, correlating with its high susceptibility to proteolysis.
We also established the optimal buffer formulation for all analyzed TRAIL variants, namely, neutral or near-neutral pH, ionic strength over 1 M and 10% (v/v) glycerol. Under these conditions, the native protein structure could be maintained even after the dissociation of the zinc ion, the cofactor crucial for TRAIL bioactivity and specificity. Finally, the current study highlights the applicability of the high-screening approach DSF in the initial steps of optimizing protein formulation.
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